ABCL
EquityAbCellera Biologics Inc.
Health Care · Biotechnology
$3.61
+3.61 (+0.00%)
Open
N/A
Day Range
$3.36 - $3.62
52W Range
$1.89 - $6.52
Volume
5M
Price History
Key Statistics
Market Cap
N/A
P/E Ratio
N/A
EPS
N/A
Dividend Yield
N/A
P/B Ratio
N/A
Payout Ratio
N/A
ROE
N/A
Debt/Equity
N/A
Latest News
Why AbCellera (ABCL) Is Up 11.5% After Narrowing Losses And Expanding ESOP Share Capacity – And What's Next
AbCellera Biologics (ABCL) Pivots to Clinical Stage as 2025 Revenue Hits $75M
AbCellera Biologics Inc. Q4 2025 Earnings Call Summary
AbCellera Biologics Inc (ABCL) Q4 2025 Earnings Call Highlights: Navigating Growth Amidst Challenges
AbCellera Biologics Inc. (ABCL) Reports Q4 Loss, Tops Revenue Estimates
About AbCellera Biologics Inc.
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; AbbVie Inc.; and partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.
www.abcellera.com →Dividend Safety
Assessment based on payout ratio, debt levels, profit margins, and dividend growth track record.
Borderline
Based on 4 fundamental factors
Analysis Tools
Share
No dividend data available for ABCL
Dividend Safety
Assessment based on payout ratio, debt levels, profit margins, and dividend growth track record.
Borderline
Based on 4 fundamental factors
Loading financial data...
Revenue & Earnings
No financial statement data available for ABCL.